These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21509803)

  • 21. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex.
    Ohoyama K; Yamamura S; Hamaguchi T; Nakagawa M; Motomura E; Shiroyama T; Tanii H; Okada M
    Eur J Pharmacol; 2011 Feb; 653(1-3):47-57. PubMed ID: 21147094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.
    Pompeu TE; Alves FR; Figueiredo CD; Antonio CB; Herzfeldt V; Moura BC; Rates SM; Barreiro EJ; Fraga CA; Noël F
    Eur J Med Chem; 2013 Aug; 66():122-34. PubMed ID: 23792350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.
    Park CM; Kim SY; Park WK; Choi JH; Seong CM
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5221-4. PubMed ID: 20655748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
    Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
    Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions of N-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-2-aryl-2-yl-acetamides and 1-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-3-aryl-2-yl-ureas with dopamine D2 and 5-hydroxytryptamine 5HT(1A) receptors.
    Sukalovic V; Ignjatovic D; Tovilovic G; Andric D; Shakib K; Kostic-Rajacic S; Soskic V
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3967-72. PubMed ID: 22607670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments.
    Harrison-Read PE
    J Psychopharmacol; 2009 Nov; 23(8):899-907. PubMed ID: 18635692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus.
    Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Viti B; Santagada V; Caliendo G
    Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
    Gogos A; Kwek P; Chavez C; van den Buuse M
    J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands.
    Liu Z; Chen X; Sun P; Yu L; Zhen X; Zhang A
    Bioorg Med Chem; 2008 Sep; 16(18):8335-8. PubMed ID: 18783955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors.
    Auclair A; Blanc G; Glowinski J; Tassin JP
    J Neurochem; 2004 Oct; 91(2):318-26. PubMed ID: 15447665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
    López-Rodríguez ML; Rosado ML; Benhamú B; Morcillo MJ; Sanz AM; Orensanz L; Beneitez ME; Fuentes JA; Manzanares J
    J Med Chem; 1996 Oct; 39(22):4439-50. PubMed ID: 8893838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New potent 5-HT(2A) receptor ligands containing an N'-cyanopicolinamidine nucleus: Synthesis and in vitro pharmacological evaluation.
    Fiorino F; Severino B; Magli E; Perissutti E; Frecentese F; Esposito A; Incisivo GM; Ciano A; Massarelli P; Nencini C; Santagada V; Caliendo G
    Eur J Med Chem; 2012 Jan; 47(1):520-9. PubMed ID: 22133459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of noradrenergic alpha1, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs.
    Ma J; Ye N; Cohen BM
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):647-57. PubMed ID: 16487641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
    Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
    J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.